News
Schrödinger expects to initiate a Phase 1 clinical trial of SGR-1505 in patients with relapsed or refractory B-cell lymphoma in the second half of 2022. “Based on the preclinical data for SGR ...
NEW YORK, May 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback